{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T05:05:53Z","timestamp":1726290353337},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,8]]},"DOI":"10.7759\/cureus.31230","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T11:43:36Z","timestamp":1667907816000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case Report of Anti-phospholipid Syndrome With Lower Extremity Arterial Thrombosis That Didn\u2019t Respond to Heparin and Direct Oral Anticoagulation: Ultimately, the Patient Agreed to Oral Warfarin"],"prefix":"10.7759","author":[{"given":"Zeinab A","family":"Abdulrahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayder","family":"Azeez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramy","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Kaell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.675","article-title":"Antiphospholipid syndrome","volume":"2013","author":"Lim W","year":"2013","unstructured":"Lim W. Antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2013, 2013:675-80. 10.1182\/asheducation-2013.1.675","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2007.48.6.901","article-title":"Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview","volume":"48","author":"Atanassova PA","year":"2007","unstructured":"Atanassova PA. Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview. Yonsei Med J. 2007, 48:901-26. 10.3349\/ymj.2007.48.6.901","journal-title":"Yonsei Med J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12860\/jnp.2014.03","article-title":"Catastrophic antiphospholipid syndrome: a clinical review","volume":"3","author":"Nayer A","year":"2014","unstructured":"Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol. 2014, 3:9-17. 10.12860\/jnp.2014.03","journal-title":"J Nephropathol"},{"key":"ref4","article-title":"Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus","volume":"12","author":"Somers E","year":"2002","unstructured":"Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol. 2002 ,  12:2531-6.","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8670","article-title":"Cholesterol embolization syndrome from penetrating aortic ulcer","volume":"12","author":"Nickol J","year":"2020","unstructured":"Nickol J, Richards T, Mullins J. Cholesterol embolization syndrome from penetrating aortic ulcer. Cureus. 2020, 12:e8670. 10.7759\/cureus.8670","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5847\/wjem.j.1920-8642.2016.03.012","article-title":"Infective endocarditis as a rare cause for acute limb ischemia","volume":"7","author":"Galyfos G","year":"2016","unstructured":"Galyfos G, Giannakakis S, Kerasidis S, Geropapas G, Kastrisios G, Papacharalampous G, Maltezos C. Infective endocarditis as a rare cause for acute limb ischemia. World J Emerg Med. 2016, 7:231-3. 10.5847\/wjem.j.1920-8642.2016.03.012","journal-title":"World J Emerg Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310397082","article-title":"'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010","volume":"20","author":"Bertolaccini ML","year":"2011","unstructured":"Bertolaccini ML, Amengual O, Atsumi T, et al.. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011, 20:191-205. 10.1177\/0961203310397082","journal-title":"Lupus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.067314","article-title":"Assessment of the 2006 revised antiphospholipid syndrome classification criteria","volume":"66","author":"Kaul M","year":"2007","unstructured":"Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007, 66:927-30. 10.1136\/ard.2006.067314","journal-title":"Ann Rheum Dis"},{"key":"ref9","unstructured":"Top 10 Points Patients Should Know About Classification and Diagnosis of Antiphospholipid Syndrome. (2020). Accessed. 9\/12\/2022: https:\/\/www.hss.edu\/conditions_top-ten-points-classification-versus-diagnosis-antiphospholipid-syndrome-how-are-they-...."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo V","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, et al.. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018, 132:1365-71. 10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller SC","year":"2022","unstructured":"Woller SC, Stevens SM, Kaplan D, et al.. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv. 2022, 6:1661-70. 10.1182\/bloodadvances.2021005808","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/107024-a-case-report-of-anti-phospholipid-syndrome-with-lower-extremity-arterial-thrombosis-that-didnt-respond-to-heparin-and-direct-oral-anticoagulation-ultimately-the-patient-agreed-to-oral-warfarin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:52Z","timestamp":1707507832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/107024-a-case-report-of-anti-phospholipid-syndrome-with-lower-extremity-arterial-thrombosis-that-didnt-respond-to-heparin-and-direct-oral-anticoagulation-ultimately-the-patient-agreed-to-oral-warfarin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.31230","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,8]]}}}